Advantame--an overview of the toxicity data.

Advantame is an N-substituted (aspartic acid portion) derivative of aspartame that is similar in structure to neotame, another N-substituted aspartame. An extensive series of studies, were conducted on advantame to define the pharmacokinetics and metabolism in various species, subchronic and chronic toxicity in the rat and dog, carcinogenicity in the rat and mouse, genotoxicity, reproductive, and developmental toxicity, and human tolerability studies. The results of these studies, presented in overview in the present publication, and in greater detail in the accompanying publications, show that advantame is well tolerated by both animals and humans and does not possess systemic toxicity. The metabolic data demonstrate that the animal species used in the toxicity testing are relevant to the evaluation of human safety. The no-observed-adverse-effect levels (NOAELs) identified in the animal studies in which advantame was administered in the diet were generally the highest doses tested. Under the anticipated conditions of use, the predicted intakes of advantame are about 20,000- to 70,000-fold lower than the identified animal study NOAEL values. The results of the animal toxicology and human trial data support the safety of use of advantame in food.

In vitro and in vivo assessment of the mutagenic activity of N-[N-[3-(3-hydroxy-4-methoxyphenyl) propyl]-α-aspartyl]-L-phenylalanine 1-methyl ester, monohydrate (advantame).

Advantame (N-[N-[3-(3-hydroxy-4-methoxyphenyl) propyl]-α-aspartyl]-L-phenylalanine 1-methyl ester, monohydrate), an N-substituted analogue of aspartame, has been developed as a high-intensity sweetener. It is approximately 100 and 20,000 times sweeter than aspartame and sucrose, respectively. In this study the safety of advantame has been evaluated using a series of in vitro and in vivo genotoxicity assays including, bacterial mutation, mammalian cell mutation, and mouse micronucleus tests. Advantame did not induce reverse mutations in Salmonella typhimurium and Escherichia coli at concentrations of up to 5000 µg/plate. In the mammalian cell mutation assay, advantame did not induce mutation at the Hprt locus of L5178Y mouse lymphoma cells in two independent experiments, either in the absence or presence of S9. In vivo, there was no effect on the incidence of micronucleated immature or mature erythrocytes in bone marrow after oral administration of the test substance at any dose level (up to 2000 mg/kg body weight) or sampling time (24 and 48 h). The results of these studies demonstrate that advantame is without genotoxic potential.

Chronic toxicity and carcinogenicity of N-[N-[3-(3-hydroxy-4-methoxyphenyl) propyl]-α-aspartyl]-L-phenylalanine 1-methyl ester, monohydrate (advantame) in the rat.

Groups of 55 male and 55 female Han Wistar rats were administered advantame (98.9-99.8% purity) in the diet at concentrations of 0, 2000, 10,000, or 50,000 ppm for 104 weeks, following parental exposure to the same levels from prior to mating and throughout gestation. Additional groups of 20 rats/sex and 10 rats/sex were dosed for a period of 52 weeks and constituted the toxicity and reversibility phases of the study. Achieved doses of advantame over the carcinogenicity study were 0, 97, 488, and 2621 mg/kg body weight/day in males and 0, 125, 630, and 3454 mg/kg body weight/day in females, respectively. A high incidence of a pale and swollen anus and changes in fecal composition were observed in the high-dose groups. There was no effect of treatment on mortality. Body weight gain in the high-dose males (50,000 ppm) was slightly reduced compared to controls after 52 and 104 weeks of treatment; the decrease was not considered to be of toxicological significance, but due to the non-nutritive nature of the high dietary concentration of advantame. During the toxicity phase, food conversion efficiency was slightly decreased in both sexes, at the 50,000 ppm dose level. Given the non-nutritive content of the diet, this finding was not considered biologically significant. There were no relationships between treatment and the results of hematological or urinalysis investigations. Clinical chemistry evaluations showed consistently lower plasma urea concentrations in both sexes treated at 50,000 ppm, which was reversed during the 6-week recovery phase following 52 weeks of treatment, indicating a lack of permanent effects. Terminal investigations at both the 52 and 104-week revealed a number of intergroup differences in absolute and/or relative organ weights; however, the differences did not show dose-response relationships, were minor in nature, and/or occurred only in one sex, and were not associated with any pathological findings, and they were considered not to be treatment-related. Evaluation of the histopathology of the carcinogenicity phase animals revealed an increased incidence of pancreatic islet cell carcinomas in males (incidence rates of 0/55, 1/55, 2/55, and 3/55 in the 0, 2000, 10,000, or 50,000 ppm groups, respectively) and of mammary gland adenomas in the high-dose females (incidence rates of 0 in the control through 10,000 ppm dose groups and 4/41 in the 50,000 ppm dose group). The incidence rates of these tumors did not attain statistical significance and/or remained within background historical control values, and they were considered to be unrelated to advantame treatment. The no-observed-adverse-effect level was considered to be 50,000 ppm in the diet, the highest concentration tested, equivalent to 2621 and 3454 mg/kg body weight/day in males and females, respectively. Advantame was concluded to be without carcinogenic activity.

H-aggregation of Methyl Orange at the Interface between the Water Phase and Oil Phase in a Water-in-Oil Microemulsion

Methyl orange dissolved in a water-in-oil microemulsion was examined by UV-VIS absorption spectroscopy and differential scanning calorimetry (DSC). Methyl orange showed two temperature-dependent peaks at 416 and 354 nm in the microemulsion. The former was attributed to a methyl orange monomer, and the latter to aggregates of the dye in the parallel orientation (H-aggregates) at the interface between the water phase and the oil phase in the microemulsion. The position of methyl orange in the microemulsion was verified by DSC analysis.

Monoclonal antibodies define antigenic regions on the major internal protein p24 of bovine leukemia virus (BLV).

The major core protein p24 of bovine leukemia virus (BLV) was characterized by ten monoclonal antibodies. Competitive binding assays were performed in order to analyze the topography of the antigenic determinants by enzyme-linked immunosorbent assay. At least three independent antigenic regions were demonstrated on the BLV p24 molecule.

Polymyositis associated with dissecting aneurysm of arteries and intracerebral hemorrhage.

Dissecting aneurysm and stroke are a rare complication of polymyositis. The present report describes an autopsy case of a 53-year-old woman, who suffered from polymyositis accompanied by dissecting aneurysms of right external iliac and right renal arteries, and furthermore, intracerebral hemorrhage. The latter was caused by necrotizing angiitis. The patient had no abnormal anatomical changes such as coarctation of aorta, aortic stenosis, bicuspid aortic valve or Marfan's syndrome. Atherosclerosis in the patient was mild, and cystic medial necrosis of aorta and arteries was not found. Since the patient was attacked by dissections of arteries following long-term steroid therapy, a possibility can be raised that arterial dissection was attributable to steroid treatment besides necrotizing angiitis complicating in polymyositis.

Sulfate esters of hydroxymethyl-methyl-benz[a]anthracenes as active metabolites of 7,12-dimethylbenz[a]anthracene.

7-Hydroxymethyl-12-methylbenz[a]anthracene (7-HMBA) and 12-hydroxymethyl-7-methylbenz[a]anthracene (12-HMBA), carcinogenic major metabolites of 7,12-dimethylbenz[a]anthracene (DMBA) in untreated rat liver, showed high mutagenic activities toward Salmonella typhimurium TA 98 after preincubation with a sulfotransferase-PAPS system consisting of ATP, sodium sulfate, and a post-mitochondrial fraction (S-9) or a soluble supernatant fraction (S-105) from untreated rat liver. The 7- and 12-HMBAs themselves induced His+ mutation in TA 98 only slightly after preincubation with S-9 in the presence of an NADPH-generating system. Mutagenicity of DMBA toward TA 98 after preincubation with S-9 in the presence of the NADPH-generating system was remarkably enhanced by the addition of ATP and sodium sulfate. The active metabolites, 7-HMBA sulfate and 12-HMBA sulfate, were isolated from these preincubation systems and identified by comparison with the corresponding synthetic specimens. The sulfuric acid ester conjugates were potent mutagens toward TA 98 in the absence of rat liver subcellular fractions. The conjugates bound covalently at significant rates to calf-thymus DNA as well as to S-105 proteins at 37 degrees and pH 7.4 through the 7- or 12-methylene carbon with concomitant loss of their sulfate group. In the presence of S-105, glutathione inhibited the mutagenicity of the metabolically formed or exogenously added 7- and 12-HMBA sulfates. The non-mutagenic glutathione conjugates were isolated from the incubation mixtures and identified as S-(12-methylbenz[a]anthracen-7-yl)methylglutathione from 7-HMBA or its sulfate and S-(7-methylbenz[a]anthracen-12-yl)methylglutathione from 12-HMBA or its sulfate.